CD274 and cancer: Deployment of immuno-oncology (IO) treatment in ESBC is gaining momentum, with ICI antibodies targeting the PD-1/PD-L1 axis (namely pembrolizumab, nivolumab, and durvalumab) garnering substantial clinical attention and designation as the standard of care (SOC) within some cancer subtypes (Nanda et al., 2020; Schmid et al., 2020).